Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3465 - The differences in recurrence and survival of extremity liposarcoma subtypes

Date

11 Sep 2017

Session

Poster display session

Presenters

Melissa Vos

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

M. Vos1, H. Kosela Paterczyk2, P. Rutkowski2, G.J.L.H. van Leenders3, M. Normantowicz4, A. Lecyk4, S. Sleijfer5, K. Verhoef6, D.J. Grünhagen6

Author affiliations

  • 1 Medical Oncology/surgical Oncology, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL
  • 2 Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 3 Pathology  , Erasmus MC Cancer Institute, Rotterdam/NL
  • 4 First Faculty Of Medicine, Medical University of Warsaw, Warsaw/PL
  • 5 Medical Oncology, Erasmus MC Cancer Institute, Rotterdam/NL
  • 6 Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam/NL
More

Resources

Abstract 3465

Background

Liposarcomas (LPS) are most frequently located in the extremity and recur often, locally as well as on distant sites. There are currently no studies comparing the differences between the different LPS subtypes specifically on this primary site. The aim of this study is to map the differences in recurrence and survival of extremity LPS.

Methods

Two retrospective databases (Rotterdam-R, Warsaw-W) of patients treated for primary LPS located in the extremities from 1985-2015 in two tertiary referral centers were used to analyze recurrence patterns (local/distant) and survival.

Results

In total, 456 patients were identified: 192 with well differentiated LPS (WDLPS), 172 myxoid LPS (MLPS), 54 pleomorphic LPS (PLPS), 23 dedifferentiated LPS(DDLPS) and 15 other subtypes (excluded from further analysis). A difference between the two datasets was the frequency of (neo)adjuvant radiotherapy (R: 34.9% vs. W: 81.5%). In the Rotterdam cohort, local recurrence (LR) was observed most frequent in DDLPS (4/13, 5-year LR free survival 56.6%), followed by WDLPS (26/113, 64.9%), PLPS (3/20, 78.6%) and MLPS (10/77, 84.0%, p = 0.136). In the Warsaw cohort, 5-year LR free survival was the lowest in PLPS (9/34, 67.7%), followed by DDLPS (1/10, 83.3%), MLPS (12/95, 84.9%) and WDLPS (3/79, 94.1%, p = 0.001). Distant metastases (DM) were most commonly observed in PLPS in both datasets (5-year DM free survival R: 9/20, 50.3% and W: 16/34, 44.5%), but in the Rotterdam cohort MLPS (16/77, 76.3%) was the second most common subtype with DM, compared to DDLPS (2/10, 62.5%) in Warsaw. DM in WDLPS was rare in both datasets (R:3/113, 96.3%, W: 1/79, 98.5%). 5-year overall survival (OS) did not significantly differ between the two datasets (R: 38/223, 78.5% vs. W: 32/218, 80.9%, p = 0.561), but did significantly differ between the subtypes (R: p = 0.005, W: p 

Conclusions

Patients with the four LPS subtypes show distinct patterns of LR, DM and OS. Despite the differences in recurrence, treatment and follow up, OS did not differ significantly between the two expertise centers.

Clinical trial identification

Legal entity responsible for the study

Erasmuc MC Rotterdam

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.